Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

Financial health

Aura Biosciences, Inc. financial health

Start with the overall verdict and the rule-based risk checks for AURA, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Resilient

Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.

Cash and investments cover debt Healthy short-term liquidity Moderate leverage

Cash & Investments

$114.73M

Debt Cushion

$97.74M

Current Ratio

7.1x

Interest Coverage

N/A

Risk checks

3 of 7 flagged

  • Debt repayable from cash flow

    Negative FCF

    Passes when: Free cash flow could repay all debt within 5 years

  • Stable Altman Z-Score

    4.37 → 0.83

    Passes when: Z-Score is not falling while below the 2.99 safe zone

  • Limited dilution

    +15.6%/yr

    Passes when: Diluted share count grows less than 2% a year

  • Positive equity

    Positive

    Passes when: Shareholders' equity is above zero

  • Short-term liquidity

    7.1×

    Passes when: Current assets are at least 1× current liabilities

  • Manageable net debt

    Net cash

    Passes when: Net debt is below 3× EBITDA

  • Tangible equity base

    0.0%

    Passes when: Goodwill and intangibles are below 50% of equity

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

Piotroski F-Score

Weak

2 / 9

Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.

Altman Z-Score

Safe zone

10.02

Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$84.79M

Q1 2026

3Y -7.6%1Y +42.5%

Quick Ratio

7.1x

Q1 2026

Current Ratio

7.1x

Q1 2026

Cash Ratio

5.1x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$16.99M

Q1 2026

3Y -2.1%1Y -2.2%

Debt/Equity

0.2x

Q1 2026

Debt/Assets

0.1x

Q1 2026

Interest Coverage

—

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$0.00

Q1 2026

Assets

$137.68M

Q1 2026

3Y -12.3%1Y -18.7%

Liabilities

$30.43M

Q1 2026

3Y +0.7%1Y -6.4%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

+15.6%

FY2020–FY2025 compound rate

Stock-based compensation

$14.63M

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

None

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does Aura Biosciences, Inc. compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Immunome, Inc.

IMNM:NASDAQ

$2.22B0.010.013.10—14.6914.6914.53

Aktis Oncology, Inc.

AKTS:NASDAQ

$893.27M-0.080.040.43—7.377.371.21

Oculis Holding AG

OCS:NASDAQ

$471.63M0.010.010.85—5.965.962.21

Ocugen, Inc.

OCGN:NASDAQ

$280.88M-2.720.76Net cash—1.061.060.81

Bicycle Therapeutics plc

BCYC:NASDAQ

$236.22M0.030.022.88—11.0211.0211.02

Whitehawk Therapeutics Inc

WHWK:NASDAQ

$180.57M0.000.001.83—10.2610.262.59

MacroGenics, Inc.

MGNX:NASDAQ

$140.14M1.920.42Net cash—4.925.101.33

Outlook Therapeutics, Inc.

OTLK:NASDAQ

$100.54M-0.941.62Net cash—0.310.380.18

Corbus Pharmaceuticals Holdings, Inc.

CRBP:NASDAQ

$69.86M0.010.010.34—8.078.071.38

EyePoint Pharmaceuticals, Inc.

EYPT:NASDAQ

$25.66M0.070.060.357376.798.838.882.75

Questions

Financial health questions

Common questions about AURA's balance sheet, answered from the reported figures.

Is AURA's balance sheet healthy?

Aura Biosciences, Inc. (AURA) has a current ratio of 7.09, a quick read on short-term liquidity.

How leveraged is AURA?

Debt to equity is 0.16, which helps judge how much financing risk sits on the balance sheet.